PROM1 and glioma: In order to further interrogate glioma stem-cell treatment susceptibility we utilised FACS to isolate four cell subpopulations—CD133-single positive, CD44-single positive, CD133-CD44-double positive and CD133-CD44-double negative (Figure S1).